Integrated Pharmaceuticals

Integrated Pharmaceuticals, Inc. (IPI) was a specialty pharmaceutical company focused on the development of proprietary drug delivery systems for poorly soluble compounds. The company utilized its proprietary Integrated Drug Delivery System (IDDS) platform to create improved formulations of existing therapeutic agents, particularly in the areas of oncology and infectious diseases. Its lead programs included reformulated versions of amphotericin B and paclitaxel designed to enhance efficacy while reducing systemic toxicity. Although the company made significant strides in formulation science during the early 2000s, it is currently considered inactive.